Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 8Prostatic Neoplasms 7Salivary Gland Neoplasms 2Prostate Adenocarcinoma 2Triple Negative Breast Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1PSA Level Greater Than Two 1Neoplasm Metastasis 1Hormone Sensitive Prostate Cancer 1HER2 Negative Breast Cancer 1Castrate Sensitive Prostate Cancer 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms, Male 1Advanced Breast Cancer 1

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castrate Sensitive Prostate Cancer × Goserelin × 90 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡